Portfolio Thuja Capital Healthcare Fund I

Company: Cristal Therapeutics - Visit website
Fund: Thuja Capital Healthcare Fund I
Year: 2012
Status: Active

Cristal Therapeutics (formerly known as Cristal Delivery) is a pharmaceutical company developing a new class of nanomedicine based on its proprietary polymeric technologies, registered as CriPec®.  Cristal Delivery’s mission is optimise the therapeutic performance of drugs and thereby improve patient care.

Company: TheraSolve N.V. - Visit website
Fund: Thuja Capital Healthcare Fund I
Year: 2011
Status: Active

TheraSolve develops a skin patch technology (embedded electronics) to improve drug treatment compliance.

Company: Okapi Sciences N.V. - Visit website
Fund: Thuja Capital Healthcare Fund I
Year: 2008
Status: Realized

Okapi develops antiviral drug products to treat viral diseases in pet animals and livestock. The company was acquired by Aratana Therapeutics Inc.

Company: Fabpulous B.V. - Visit website
Fund: Thuja Capital Healthcare Fund I
Year: 2009
Status: Active

Fabpulous develops a handheld disposable plasma separation device with embedded in vitro diagnostic test capability (lateral flow). The first application is a rapid h-FAPB test as an aid in the early diagnosis of a heart infarct.

Company: Bioceros B.V. - Visit website
Fund: Thuja Capital Healthcare Fund I
Year: 2008
Status: Realized

Bioceros is active in the field of protein therapeutics, and offers producer cell line generation services; it also aims to develop an own therapeutic monoclonal antibody pipeline. Our position was sold to a strategic investor.

Company: argenx b.v. - Visit website
Fund: Thuja Capital Healthcare Fund I
Year: 2008
Status: Realized

argenx is monoclonal antibody company employing proprietory superior therapeutic antibody discovery platform to develop own antibody product portfolio.

Company: DCPrime B.V. - Visit website
Fund: Thuja Capital Healthcare Fund I
Year: 2010
Status: Realized

DCPrime is a biotech company with a proprietary allogeneic dendritic cell line as a platform to derive and develop the next generation therapeutic dendritic cancer vaccines.

Company: NightBalance B.V. - Visit website
Fund: Thuja Capital Healthcare Fund I
Year: 2011
Status: Active

NightBalance is a medtech company developing and commercializing a patient-friendly device to treat positional sleep apnea.